Opinion

Video

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

Video content above is prompted by the following question(s):

  • How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Related Content
Patients with an inflammatory transcriptome profile at 3 months had a greater risk of an infection. | Image credit: Saiful52 - stock.adobe.com
September 4th 2025

Immune Profiling May Help Gauge Infection Risk in Patients With CLL

Jared Kaltwasser
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
September 4th 2025

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

It was difficult to generate strong conclusions from the existing data due to the “sparse and heterogeneous” nature of the cardiovascular data reported in the trials. | Image credit: Tima - stock.adobe.com
September 4th 2025

Age, BTKi Use May Contribute to Cardiovascular Risk in CLL

Jared Kaltwasser
The new research points to the potential of AP-1 and stromal interactions as promising targets to overcome resistance and improve outcomes in CLL. | Image credit: jarun011 - stock.adobe.com
September 4th 2025

AP-1 as a Therapeutic Focus in CLL

Kimberly Rath, PharmD
Overall, participants with CLL had significantly lower MLR values compared with the healthy donors. | Image credit: angellodeco - stock.adobe.com
September 4th 2025

Monocyte-to-Lymphocyte Ratio Linked With Functional Status in CLL

Jared Kaltwasser
When CLL treatment types were compared, BTKi recipients reported better social/family well-being than those under surveillance. In contrast, venetoclax recipients reported lower physical well-being than the surveillance group. | Image credit: Kay Abrahams - stock.adobe.com
September 4th 2025

Gender-Specific Approaches to CLL Care May Improve QOL Outcomes

Kimberly Rath, PharmD

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo